This is consistent with the proliferation of calls for early consideration of genomic testing in patients manifesting unexplained hypogammaglobulinemia, elevated IgM, or distinct CVID phenotypes, particularly with coexisting lymphoproliferation or cytopenias [5]. This evidence concerns the gene CD40LG and agammaglobulinemia.